Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-α2a in patients with HIV

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 16, Issue 4, 1997, Pages 247-253

  Fischl, Margaret A ^a   Richman, Douglas D ^b   Saag, Michael ^c   Meng, Tze Chiang ^b   Squires, Kathleen E ^c   Holden Wiltse, Jeanne ^d   Meehan, Patricia M ^d  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of Alabama at Birmingham   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Combination therapy; HIV infection; Interferon

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; INTERFERON; RECOMBINANT ALPHA2A INTERFERON; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ANEMIA; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VIRUS INFECTION;

ADULT; ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; VIRUS REPLICATION; ZALCITABINE; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0030734519     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199712010-00005     Document Type: Article

References (20)

1. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987;317:185-91.
2. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo controlled-trial. Ann Intern Med 1990;112:727-37.
3. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled-trial in persons with fewer than 500 CD4 positive cells per cubic Millimeter. N Engl J Med 1990;322:941-9.
4. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992;327:581-7.
5. Spruance SL, Pavia AT, Peterson D, et al. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine: a randomized, double-blind clinical trial. Ann Intern Med 1994;120: 360-8.
6. Dolin R, Amato DA, Fischl MA, et al. Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or nor previous experience with zidovudine. Arch Intern Med 1995;155:1-14.
7. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;246:1155-8.
8. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994;68:1660-6.
9. D' Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy: AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med 1995;122: 401-8.
10. Meng TC, Fischl MA, Boota AM, et al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection: a phase I/II study. Ann Intern Med 1992;116:13-20.
11. Collier AC Coombs RW, Fischl MA, et al. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med 1993;119:786-93.
12. Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter: North America HIV Working Party. N Engl J Med 1995;333:1662-9.
13. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
14. Shirazi Y, Pitha PM. α-interferon inhibits early stages of the human immunodeficiency virus type 1 replication cycle. J Virol 1992;66:1321-8.
15. Meylan PRA, Guatelli JC, Munis JR, Richman DD, Kornbluth RS. Mechanisms for the inhibition of HIV replication by interferons-α, -β, -γ in primary human macrophages. Virol 1993;193:138-48.
16. Hartshorn KL, Vogt MW, Chou TC, et al. Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha-A interferon. Antimicrob Agents Chemother 1987;31:168-72.
17. Johnson VA, Merrill DP, Videler JA, et al. Two-drug combinations of zidovudine, didanosine and recombinant interteron-α inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J Infect Dis 1991;164:646-55.
18. Kovacs JA, Deyton L, Davey R, et al. Combination zidovudine and interferon-α therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989;111:280-7.
19. Krown SE, Gold JWM, Niedzwiecki D, et al. Interferon-α with zidovudine: safety, tolerance and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med 1990;112:812-21.
20. n1 and concomitant zidovudine in patients with AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr Hum Retrovirol 1991;4:1-10.